An observational study in Adult Immunoblastic Lymphoma, Central Nervous System Non-Hodgkin Lymphoma and Childhood Immunoblastic Lymphoma, sponsored by Children's Oncology Group. Completed at 130 sites in 4 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2023-10-03.
Sponsored by Children's Oncology Group · Observational
Among 432 studies in Lymphoma, Large-Cell, Immunoblastic with a site in United States — 2 open to participants now, 5 under way, none of them phase 3. Lymphoma, Large-Cell, Immunoblastic · United States.
Among the 432 studies in Lymphoma, Large-Cell, Immunoblastic with a site in United States, this one is the 8th largest by enrollment of the 28 observational ones that give a count, is one of 27 that started in 2005, is one of 28 observational ones, and was the 385th registered.
491 studies on the registry are indexed under Lymphoma, Large-Cell, Immunoblastic; 2 are open to participants now.
Browse Lymphoma, Large-Cell, Immunoblastic studies →2 of the 432 studies in Lymphoma, Large-Cell, Immunoblastic with a site in United States are open now. Recruiting first, the newest first:
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 65+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Lymphoma, Large-Cell, Immunoblastic studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
432 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 185 · Phase 2 178 · Phase 3 35 · Phase 4 1
First in 1988; this study’s year is marked. 27 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 174 is above the median of 55 across 30 observational studies indexed under Lymphoma, Large-Cell, Immunoblastic.
Median enrollment 35 across the 315 interventional studies, 53 across the 28 observational. Of the 397 that completed or were terminated, 97 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 432 have an industry lead sponsor. The 10 most frequent:
Children's Oncology Group is the lead sponsor of 448 studies on the registry; 36 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Children's Oncology Group has 1 study filed under Lymphoma, Large-Cell, Immunoblastic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 432 studies in Lymphoma, Large-Cell, Immunoblastic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This research study is collecting and storing tissue samples from patients with rare or cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
OBJECTIVES:
I. To determine the clinical features, treatment, and outcome of patients with rare or cutaneous pediatric non-Hodgkin lymphoma (NHL).
II. To determine the pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry.
III. To establish a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers.
IV. To determine sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies.
OUTLINE:
On study data will include presenting symptoms and signs, physical description of the tumor if it is on the skin, results of metastatic evaluation, stage (if available), blood count, markers, and the results of viral serologies. Any existing underlying conditions that could predispose to lymphoma will also be noted. Demographic and outcomes data will be stored and maintained by the COG Research Data Center. Demographic data will be linked to the specimen data in the BPC database.
The approach of this study is prospective data collection, including central pathologic review, relevant biologic studies, submission of material to the Biopathology Center (BPC) and collection of diagnostic and outcome data. Participants will be registered with a standard COG registration form for documentation of age, gender, race, date of diagnosis, initial presentation, initial work-up, and stage according to the standard staging for the specific disease, initial diagnostic procedure, and institutional diagnosis. Tissue will be sent according to guidelines in Section 4.0. Follow-up data, including relapse or progression and vital status will be reported annually for 5 years.
Patients will be followed annually for 5 years and data will be collected including vital status, evidence/absence of disease, type of treatment received, progression/relapse and whether the patient continues on study.
PATIENTS WITH RARE OR CUTANEOUS NHL
Inclusion Criteria:
Diagnosis of NHL
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
See Detailed Description
Other: Cytology Specimen Collection Procedure
Correlative studies
Also known as: Cytologic Sampling
Clinical features, treatment, and outcomes
Time frame: Up to 5 years
Pathologic and biologic features of these diseases, including molecular diagnostics and flow cytometry
Time frame: Up to 5 years
Establishment of a bank of these pathologically reviewed diseases and make specimens of blood and tissue available to qualified researchers
Time frame: Up to 5 years
Sub-groups of these diseases that could be targeted for future biologic, pathologic, or therapeutic studies
Time frame: Up to 5 years
Showing the first 100 of 130 sites across 4 countries. Choose a country and city above to see the rest.
Ran from May 2005 to primary completion in Jun 2007, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lymphoma, Large-Cell, Immunoblastic →